Recombinant full-length parathyroid hormone (1-84): A viewpoint by James Whitfield

Drugs

Volumn 66, Issue 18, 2006, Pages 2382-

  Whitfield, James ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RECOMBINANT PARATHYROID HORMONE;

BONE DENSITY; BONE MINERALIZATION; BONE TURNOVER; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; LOW DRUG DOSE; MUSCLE WEAKNESS; NONHUMAN; NOTE; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; RISK FACTOR; SPINE FRACTURE;

EID: 33846113022     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666180-00009     Document Type: Note

References (7)

1. Tregear GW, van Rietschoten J, Greene E, et al. Solid-phase synthesis of the biologically active N-terminal 1-34 peptide of the human parathyroid hormone. Hoppe Seylers Z Physiol Chem 1974; 355(4): 415-421
2. Whitfield JF. Osteoporosis-treating parathyroid hormone peptides: What are they? What do they do? How do they do it? Curr Opin Invest Drugs 2006; 7(4): 349-359
3. NPS® Pharmaceuticals. NPS receives approvable letter for PREOS NDA. 2006 Mar 10 [online]. Available from URL: http://www.npsp.com/news/releasetxt. php?ReqId=830043 [Accessed 2006 Nov 15]
4. 2 (ostabolin). Calcif Tissue Int 1996; 58(2): 81-87
5. Whitfield JF, Morley P, Willick G, et al. Comparison of the ability of recombinant human parathyroid hormone, rhPTH-(1-84) and hPTH-(1-31)NH2 to stimulate femoral trabecular bone growh in ovariectomized rats. Calcif Tissue Int 1997; 60(1): 26-29
6. Vahle JL, Long GG, Sandusky, G, et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004; 32(4): 426-438
7. Morley P. Delivery of parathyroid hormone for the treatment of osteoporosis. Expert Opin Drug Deliv 2005; 2(6): 993-1002